Disc Medicine Reports Positive Initial Data from RALLY-MF Phase 2 Trial for Myelofibrosis and Anemia Treatment.

Disc Medicine has presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis. The trial demonstrated substantial reductions in hepcidin and increases in iron levels, resulting in positive impacts on clinically meaningful measures of anemia across various patient subgroups. Treatment with DISC-0974 was associated with improvements in fatigue scores and was generally well-tolerated.